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Abstract
Background: The ACTION study (Attention deficit hyperactivity disorder Controlled Trial Investigation Of a Non-
stimulant) is a multi-center, double-blind, randomized cross-over trial of the non-stimulant medication,
Atomoxetine, in children and adolescents with attention deficit hyperactivity disorder (ADHD). The primary aims are
to examine the efficacy of atomoxetine for improving cognition and emotional function in ADHD and whether any
improvements in these outcomes are more pronounced in participants with comorbid anxiety; and to determine if
changes in these outcomes after atomoxetine are more reliable than changes in diagnostic symptoms of ADHD.
This manuscript will describe the methodology and rationale for the ACTION study.
Methods: Children and adolescents aged 6 - 17 y with ADHD will be enrolled. Clinical interview and validated
scales will be used to confirm diagnosis and screen for exclusion criteria, which include concurrent stimulant use,
and comorbid psychiatric or neurological conditions other than anxiety. Three assessment sessions will be
conducted over the 13-week study period: Session 1 (Baseline, pre-treatment), Session 2 (six weeks, atomoxetine or
placebo), and Session 3 (13 weeks, cross-over after one-week washout period). The standardized touch-screen
battery, “IntegNeuro™”, will be used to assess cognitive and emotional function. The primary measure of response
will be symptom ratings, while quality of life will be a secondary outcome. Logistic regression will be used to
determine predictors of treatment response, while repeated measures of analysis will determine any differences in
effect of atomoxetine and placebo.
Results: The methodology for the ACTION study has been detailed.
Conclusions: The ACTION study is the first controlled trial to investigate the efficacy of atomoxetine using objective
cognitive and emotional function markers, and whether these objective measures predict outcomes with atomoxetine
in ADHD with and without comorbid anxiety. First enrollment was in March 2008. The outcomes of this study will be a
significant step towards a ‘personalized medicine’ (and therefore a more efficient) approach to ADHD treatment.
Trial registration: Australian and New Zealand Clinical Trials Registry ANZCTRN12607000535471.
Background
Attention deficit hyperactivity disorder (ADHD) affects
at least one child or young person in every classroom
worldwide, with prevalence estimates ranging between 2
and 16% [1]. It is the most common psychiatric disorder
in children and adolescents, and continues into
adulthood in a majority of cases [2]. Problems experi-
enced by children and adolescents with ADHD include
difficulties with sustaining attention and/or hyperactiv-
ity/impulsivity. These problems impact unfavorably on
the young person’s everyday functioning [3], as well as
the health-related quality of life of themselves and their
families [4].
Stimulant medications are the most common pharma-
cologic treatment for ADHD [5], acutely improving
symptoms in 60 – 90% of patients [2,6-8]. However,
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are contraindications to stimulants, non-stimulant drugs
are a viable alternative. Increasingly, non-stimulant med-
ications such as atomoxetine (ATMX) are considered
when comorbid conditions, such as anxiety, are present
[9]. ATMX is purported to be a viable alternative to sti-
mulant treatment for ADHD, with particular efficacy for
children and adolescents with ADHD who are prone to
problems with inhibition, anxiety and substance abuse
[10].
ATMX has been approved by the US Food and Drug
Administration for the treatment of ADHD [7], and has
a demonstrated response rate of up to 63.5% [11-13],
comparable to that of stimulant treatment [14]. Com-
pared to stimulant drugs, ATMX has a lower potential
for abuse or misuse [7,15], and has the advantage of
once daily dosing and continuous coverage [15]. To
date, the focus has been on efficacy studies, to deter-
mine if treatment with ATMX produces improvement
in diagnostic ADHD symptoms. Symptoms are assessed
using well-established rating scales, including the
ADHD Rating Scale IV - Parent version (ADHD-RS IV)
score [3,11,16-28], Clinical Global Impressions (CGI)
score [17,29], and Connors’ Parent and Teacher Rating
Scales: Short version [13], and the Parent-rated Hyper-
activity/Impulsivity Swanson Nolan and Pelham ratings
[29]. In terms of the effect of ADHD medications on
objective cognitive outcomes, one cross-sectional study
using historical data indicated that young people who
were medicated for ADHD (with either ATMX, methyl-
phenidate or amphetamine) performed superiorly on
objective cognitive tests compared to their non-medi-
cated ADHD counterparts, although their performance
remained poorer than that of non-ADHD controls [30].
To our knowledge, there have been no controlled trials
undertaken to determine: 1) if ATMX has efficacy for
improving cognition; and 2) if response to ATMX is
predicted by other measures of cognition in ADHD,
with and without comorbid anxiety. The ACTION study
has been designed to address this issue.
The ACTION study will be a double-blind, rando-
mized, controlled cross-over trial, to assess ADHD at
baseline, and after treatment with either ATMX or pla-
cebo. At each assessment point clinical ratings of symp-
toms will be acquired. The ACTION study will assess
cognition using a standardized, computerized battery
called ‘IntegNeuro™” (Brain Resource Ltd., Sydney,
Australia and San Francisco, USA). IntegNeuro™ has
been validated and established in ADHD [1,31,32],
thereby providing a basis for future studies seeking to
extend or replicate our findings. Cognitive markers from
IntegNeuro™ have been found to identify ADHD with
high sensitivity and specificity [1]. These markers also
correlate with brain function assessed by both EEG and
heart rate variability [1].
The findings from the ACTION study will help sup-
port a more personalized approach to treatment options
available for children and adolescents with ADHD by
examining the efficacy of ATMX in improving both sub-
jectively-rated symptom measures and objectively-
assessed performance in ADHD. It will also provide evi-
dence about which objective cognitive markers relate to
ATMX response in ADHD, and how anxiety moderates
ATMX response. An evidence-base of this kind may
help support clinicians in making decisions about if and
when to consider non-stimulants as an alternative to sti-
mulants or non-pharmacologic treatments in each indi-
vidual child or adolescent.
The primary aims of the ACTION study are to:
1. Assess whether ATMX has efficacy in improving
c o g n i t i o na n de m o t i o n a lf u n c t i o ni nc h i l d r e na n d
adolescents with ADHD.
2. Assess whether presence of co-morbid anxiety
influences the response to ATMX in children and
adolescents with ADHD in relation to cognition and
emotional function.
3. Ascertain the reliability of cognitive and emotional
function changes after ATMX compared to clinical
symptoms of ADHD, and how these correlate with
symptom changes. Please refer to Section 5 for more
detail.
The methodology for the ACTION study will be
detailed in this manuscript.
Methods/Design
1. Study regimens
Eligible and consenting participants will complete rating
scales and a computer-based test battery to assess cogni-
tive performance. Figure 1 shows the schema for the
ACTION study, which is a randomized double-blind
cross-over study. After baseline assessment, participants
will be randomized to receive either ATMX (brand
name: Strattera) or placebo (starch powder with silicone
5% in a gelatin capsule) first, for six weeks (Phase A),
before undergoing a one-week “washout” period (no
capsules). Cross-over will occur after this washout per-
iod, and participants will receive the other compound (i.
e., the compound they did not receive during Phase A)
over a second six-week period (Phase B). Baseline (Ses-
sion 1) assessments will be repeated at all time-points.
ATMX doses will be based on the participant’sw e i g h t ,
according to five pre-determined weight groups, cover-
ing the predicted weight ranges from 18 to 80 kg
(Figure 2). Both the ATMX and the placebo capsules
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Australia.
Randomization will be performed by a hospital biosta-
tistician using a centralized, pre-determined pair-wise
randomization technique, ensuring an even allocation of
participants to receiving ATMX or placebo first; while
also taking into account the expected ratios across the
five weight groups (Figure 2). Once the randomization
list has been generated, the hospital biostatistician will
forward a copy of the master list to the compounding
chemist responsible for packaging and labeling the blis-
ter cards for the study. The investigators, referring clini-
cians, and the participants will remain blinded to group
allocation. All capsule packages will be prepared prior to
the commencement of the trial, and packages will be
dispensed according to the pre-determined randomiza-
tion master list. As each participant enters the study,
they will be allocated a study ID code in the order of
numerical sequence. The corresponding blister cards
will be labeled with the ID codes and corresponding
study phase only. The participating clinicians,
investigators, and the participants will be blinded to
group allocation until the completion of the study.
1.1. Treatment delivery
The dose schedule for ATMX will be based on recom-
mendations from clinical practice and previous literature
(Figure 2) [18,33]. In addition to the drug blister packs,
ap e r s o n a l i z e d“Take Home Package” booklet will be
provided to parents/guardians of the participants, which
will include a Day Counter log book to help parents
keep track of their child’sc o m p l i a n c e( v i ad a i l yt i c k
boxes parents can mark off whenever their child takes
their daily dose). Participants will be asked to take their
capsules at the same time each morning. Drug blister
packs and “Take Home Package” booklets for use during
Phase A and B will be given to the parents at the end of
Session 1 and Session 2 respectively. At the subsequent
appointment, parents will be required to return their
completed “Take Home Package” booklet, along with
the drug blister packs regardless of their child’s compli-
ance, to enable the investigators to record any missed
doses.
Figure 1 Illustration of the ACTION study schema. W = washout period. Eligibility assessment (screening) included the ADHD-RS IV and
ADISC. Sessions 1, 2, and 3 included ADHD-RS IV, CPRS-R, DASS, BRISC, CGI, PedsQL (parent and teenager reports), and the IntegNeuro™battery.
The WPREMB-R was to be done on a weekly basis during Phases A and B.
Figure 2 Atomoxetine dosage schedule. Week 1 is the initiation dose, with approximately 0.5 mg.kg
-1 for each patient group; weeks 2-6 reach
the target dose of approximately 1.2 mg.kg
-1 for each group (with minimum dose of 1.0 mg.kg
-1 and maximum dose of 1.4 mg.kg
-1).
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Figure 3 lists the inclusion and exclusion criteria for the
ACTION study. Eligibility criteria include normal body
mass for age and gender [34], age of 6 to 17 years
(inclusive), and a primary diagnosis of ADHD. Both
boys and girls will be enrolled into the study. The pre-
sence of any of the exclusion criteria listed in Figure 3
will preclude the participant from enrolling into
ACTION.
2. Participant study visits
2.1. Screening (pre-Baseline)
Potentially eligible patients will undergo a clinical exami-
nation by a participating clinician. A primary diagnosis of
ADHD will be based on Diagnostic and Statistical Man-
ual of Mental Disorders - Fourth edition criteria [35]. The
ADHD-RS IV will be used to confirm ADHD diagnosis,
ADHD subtype, and to assess symptom severity. Addi-
tionally, the Anxiety Disorders Interview Schedule for
Children (ADISC) [36] will be used to assess the presence
of comorbid conditions. The ADHD-RS IV and ADISC
scales are detailed in Section 4. They have been shown to
have excellent reliability [36], validity [37], and medium-
to-high specificity and sensitivity [38] in children and
adolescents. The purpose of the Screening visit will be to
confirm a primary diagnosis of ADHD, to determine
symptom ratings, and eligibility for the study, as deter-
mined by participating clinicians.
Participants deemed eligible for the ACTION study
will undergo a two-week washout period prior to Base-
line testing (Session 1) if they are taking any ADHD
medication at the time of Screening. Subsequent visits
occur at weeks six and 13. Appointments will be con-
firmed over the telephone at least one day prior.
Figure 3 Inclusion and Exclusion criteria for the ACTION study. ADHD = attention deficit hyperactivity disorder; DSM-IV = Diagnosis and
Statistical Manual of Mental Disorders, Edition 4.
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Prior to attending assessment sessions, participants will
be asked to refrain from consuming caffeine that day
(including coffee, chocolate milk, caffeinated soft-
drinks).
Assessments will include cognitive and emotional
function tasks using IntegNeuro™, body mass, and vali-
dated parent-reported scales for ADHD symptom sever-
ity and self-report questionnaires (Section 4). On
average, assessments will take the participants approxi-
mately two hours to complete. Upon completion of Ses-
sion 1, parents will be given their child’sf i r s tc o u r s eo f
study capsules and a “Take Home Package” booklet as
mentioned above in 1.1.
2.3. Session 2 (6 weeks; post-Phase A)
The assessments undertaken at Baseline (Session 1) will
be repeated at Session 2. Parents will be reminded to
return their child’s capsule blister packs and “Take
Home Package” booklet, so that the investigators can
record compliance to the study drugs during each study
phase. As with Session 1, on completion of Session 2
parents will be provided with their child’s next course of
study capsules and a second “Take Home Package”
booklet for use during Phase B of the study.
2.4. Session 3 (13 weeks; post-Phase B)
The assessments undertaken at Session 2 will be
repeated at Session 3, with the exclusion of the provi-
sion of capsule blister packs and “Take Home Package”
booklets.
2.5. Ethical considerations
The ACTION study will be conducted according to the
principles of the Declaration of Helsinki 2008, and
International Conference on Harmonization (ICH)
guidelines. Investigators ensure that “Good Clinical
Practice” principles will be adhered to, as outlined in 21
FDA Code of Federal Regulations CFR 312, subpart D,
“Responsibilities of Sponsors and Investigators,” 21 CFR,
part 50, 1998, and 21 CFR, part 56, 1998.
Institutional Review Board (IRB) approval is obtained
prior to patient enrolment at any clinical site. All proto-
col modifications will be submitted to each IRB for
approval before implementation. Prior to undertaking
any study-related procedures, investigators will obtain
written informed consent from each study participant
after verbal and written explanation of study aims,
methods, and potential hazards and benefits.
3. Study organization
3.1. Organizational structure
The ACTION study will be conducted across three Australian
sites
￿ Sydney: Brain Dynamics Centre laboratory located
at Westmead Hospital (lead site). It is a center of
the University of Sydney Medical School and has a
partnership with the Centre for Research into Ado-
lescents’ Health (Department of Adolescent Medi-
cine at the Children’s Hospital at Westmead (CHW)
and Westmead Hospital).
￿ Adelaide: Cognitive Neuroscience Laboratory
located at School of Psychology, Flinders University.
It has a partnership with a large community adoles-
cent mental health practice in Adelaide.
￿ Melbourne: Department of General Paediatrics at
the Royal Children’s Hospital, Melbourne.
Clinical Trial Coordinators (CTCs) will be appointed
at all three sites.
3.2. Site selection/training/recruitment
Clinical sites were selected based on the likelihood of
meeting recruitment goals and executing the protocol.
During a site initiation visit, CTCs at each site will be
trained in protocol implementation and data collection
methods. CTCs will work closely with participants and
clinicians, ensure that all instruments are completed by
participants, and function as study coordinators (i.e.,
liaise among sites, data management at their own site,
and ensure the smooth operations of the study at their
site).
3.3. Enrolment/randomization
Patients are referred to the ACTION study by partici-
pating clinicians, by faxing completed Clinical Package
forms (containing basic demographic details, body mass;
and completed ADHD-RS IV and ADISC) to their local
CTC. The site’s CTC will contact the interested patient’s
parent to formally invite them to the study, and provide
additional information and consent forms.
4. Data collection
4.1. Screening measures
Attention Deficit Hyperactivity Disorder Rating Scale-IV
(ADHD-RS IV) [39] The ADHD-RS IV will confirm
DSM-IV diagnosis and subtype of ADHD, indicated by
a score >1 in six or more items in the Inattentive and/
or Hyperactive-Impulsive sections of the scale. If a
DSM-IV diagnosis cannot be confirmed using the
ADHD-RS IV, the participant will be excluded. Total
scores will be used as a measure of symptom severity.
Clinicians will also undertake the Anxiety Disorders
Interview Schedule for DSM-IV: Child Version (ADISC:
Parent Interview Schedule) [36]. Scores of ≥4f o ra n yo f
the domains are indicative of a positive diagnosis. Parti-
cipants will be categorized as having either ADHD +
comorbid anxiety (i.e., Separation anxiety disorder,
Obsessive compulsive disorder, and/or Generalized anxi-
ety disorder [36]); or ADHD without anxiety (which
includes those with other comorbidities excluding anxi-
ety). The number of diagnosed comorbidities in total,
including anxiety and others, will also be recorded.
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4.2.1. ADHD symptom severity At each testing session
parents will complete the ADHD-RS IV, as a measure of
ADHD symptom severity.
Parents will also rate symptom severity on the Con-
ners’ Parent Rating Scale - Revised (Long version;
CPRS-R) [40]. The CPRS-R ratings will provide a second
assessment of symptom severity, providing a within-
study check on the consistency of symptom ratings. T-
scores for all 13 subscales will be recorded, where larger
T-scores indicate greater impairment.
The secondary outcomes of ACTION will be the rela-
tionships between the primary cognitive measures and
ratings obtained from the ADHD-RS IV and CPRS-R.
4.2.2. Self-reported negative feelings and self regula-
tion Negative feelings of anxiety, depression and stress
will also be assessed via self-report, using previously
established scales. The Depression Anxiety and Stress
Scale (DASS) [41] has been established in 6 to 18 year
olds with ADHD [42], and a child-worded version of
this scale has been validated against the original in the
same children completing both original (with parental
help as needed to understand questions) and child ver-
sion, in a randomized within-subjects design [43]. The
DASS questionnaire will be scored for three domains:
Depression, Anxiety, and Stress.
To assess state as well as trait anxiety, the State-Trait
Anxiety Inventory (STAI) [44] or STAI for Children
( S T A I C )[ 4 5 ]w i l lb eu s e d .T h eS T A I Ci ss u i t a b l ef o r
use in children aged 6 to 14 years, while the STAI is
suitable for those aged >14 years. The questionnaires
provide scores on both State anxiety and Trait anxiety
[46] and will be used at all three laboratory-based
sessions.
To complement the scales assessing negative feelings,
an established measure of self-regulation (the BRISC)
will be used, which captures risk for brain health versus
resilience and capacity for seeking social support [47].
The BRISC has been normed in 6 to 92 year olds [47],
and there is good correspondence between child and
adult-worded versions [41]. The BRISC score of Nega-
tivity Bias identifies a spectrum of brain health disorders
(particularly anxiety and depression) with 87% sensitiv-
ity; and it is inversely related to Emotional resilience
and social skills capacity (data not yet published). The
validation study also established the convergence
between this scale and a child-worded version in the
same randomized within-subjects design [43]. The three
BRISC scores are Negativity bias, Emotional resilience
and Social skills.
4.3. Other symptom measures
To further explore the secondary aims of the study,
other measures of ADHD symptoms will be included at
each assessment session.
Clinical Global Impression (CGI) scale [48] The CGI
Severity scale will be used at Session 1, based on the
opinion of the investigator; while the CGI Improvement
scale will be used at both Session 2 and Session 3, tak-
ing into account the opinions of both the investigator
and the parent. Rating scores for each time-point will be
recorded.
Pediatric Quality of Life Inventory (PedsQL) - Parent
report, Version 4.0 [49] The PedsQL - Parent reports
for young children (8 to 12 years old) and adolescents
(13 to 18 years old) were utilized at all three time-points
to assess the health-related quality of life, based on the
opinion of the parent. The two summary (mean) scores
of Physical health (Physical health items) and Psychoso-
cial health (Emotional, Social, and School functioning
items) will be recorded.
PedsQL - Child report and PedsQL - Teenager report
[49] The PedsQL - Child report will be given to partici-
pants aged 8 to 12 years, while the PedsQL - Teenager
report will be provided to those aged 13 to 18 years of
age. Similarly to the PedsQL - Parent report, the sum-
mary scores for Physical health and Psychosocial health
will be recorded for analysis.
Weekly Parent Rating of Evening and Morning Beha-
vior - Revised (WPREMB-R) This questionnaire was
developed by Eli Lilly Pty. Ltd. for monitoring morning
and late afternoon/evening behavior in children and
adolescents with ADHD who are being treated using
ATMX [50]. Six copies of the WPREMB-R will be
included in the “Take Home Package 1” booklet (Phase
A), and seven will be included in the “Take Home Pack-
age 2” booklet (Phase B), so that parents can complete
the questionnaire at the start of each week during these
phases of the study. The maximum possible score
obtainable is 33, which is indicative of poorer ADHD
behavior. Mean WPREMB-R scores will be calculated
and recorded for both Phase A and Phase B. Missing
responses in any week will exclude the participant’s data
for that study phase, since the scoring method of this
questionnaire does not permit adjustment for missing
information.
4.4. IntegNeuro™battery
The IntegNeuro™ cognitive test battery is made up of
13 different tasks which require a total of approximately
50 minutes to complete. The1 3t a s k sw h i c hm a k eu p
the IntegNeuro™ test battery were designed and vali-
dated to challenge participants in six different cognitive
domains: i) Sensori-motor; ii) Learning and memory; iii)
Language; iv) Attention and working memory; v) Execu-
tive function/planning; and vi) Emotion identification
[1,31,32]. Table 1 lists the specific markers which will be
investigated in ACTION for cognitive and emotional
function and the tasks and measures used in Integ-
Neuro™ to ascertain them. Each marker is a composite
Tsang et al. Trials 2011, 12:77
http://www.trialsjournal.com/content/12/1/77
Page 6 of 11of up to three tasks, and have a combined sensitivity of
88% in children and adolescents with ADHD [1]. The
decision to focus on the Inhibition and Emotion identifi-
cation markers as primary outcomes for the ACTION
study was due to recent investigations [42,51], which led
us to hypothesize that these markers would be more
likely to improve after non-stimulant treatment in
patients with ADHD and comorbid anxiety. Research
into the cognitive markers in ADHD and their response
to different ADHD treatments is still in the early stages
so it would be premature to limit our investigations to
only two of six markers which have been validated in
ADHD. Hence, all six markers will be assessed in
ACTION due to the novelty of this study. Marker scores
are the focal dependent measures of interest, calculated
as standardized scores for the tasks each marker com-
prises (Table 1). More detailed scores for each individual
task will also be available for secondary analyses. Wil-
liams et al. (2010) provides a clear description of the
tasks which will be used in ACTION [1].
In the IntegNeuro™ cognitive battery, participants will
hear the test instructions through a pair of headphones,
and respond to the tasks by either speaking into the
microphone (attached to the headphones) or using the
touch-screen for non-verbal tasks. Participants will be
supervised throughout the test via CCTV (closed-circuit
television) from an adjacent room. Additional instruc-
tions will be given during the test if necessary. Partici-
pants will provide consent to be monitored via CCTV
by signing a Surveillance Authority Form. The CCTV
will only be used for the purpose of monitoring the
patient during the visit and no recordings will be made.
To minimize the effect of familiarization and practice
effects at subsequent testing sessions, IntegNeuro™ has
a set of parallel forms for use in repeat testing sessions,
whereby the sequences/words/patterns used in each of
the tasks have been programmed to be different between
the time-points. IntegNeuro™ will be set up to have the
participant complete the test battery corresponding to
their ACTION time-point.
5. Research endpoints
T h ep r i m a r ye n d p o i n tw i l lb ec l i n i c a l l ys i g n i f i c a n t
improvement in cognition and emotional function after
ATMX treatment assessed using IntegNeuro™ (Table
1); and in ADHD symptoms (ADHD-RS IV, CGI,
WPREMB, and CPRS-R subscales: Cognitive problems/
inattention, Hyperactivity, Conners’ ADHD index, CGI
restless-impulsive, CGI total, DSM-IV inattentive, DSM-
IV hyperactive-impulsive, and DSM-IV total). Further
analyses will be undertaken to compare the differences
in ATMX treatment effects between participants with
and without comorbid anxiety; and between ADHD
subtypes.
Part of the novelty of this trial lies in our utilization of
objective assessments for cognition and emotional func-
tion. As such, we will also determine if our objective
measures predict response to ATMX in ADHD, and in
Table 1 Six cognitive and emotional function markers, and their contributing measures
Marker Summary definition Task Measure
Cognitive:
1. Sustained
attention
(vigilance)
To maintain attention over time during continuous and
repetitive activities.
Continuous
performance
task
Reaction time, total errors
2. Impulsivity To initiate a behavior without adequate forethought; the
inability to suppress automatic responses when they are
inappropriate.
Continuous
performance
task
Go-NoGo
Errors of commission
Errors of commission
3. Intrusions The repetition of erroneous responses, even in the absence of
interfering stimuli.
Maze
Switching of
attention
Verbal
memory recall
Overrun errors
Errors (digits and letters)
Total intrusion errors
4. Inhibition The inability to suppress task-irrelevant information. Verbal
interference
Errors (word), errors (color), errors (interference)
5. Response
variability
The consistency of response time. Continuous
performance
task
Go-NoGo
Variability of reaction time
Variability of reaction time
Emotional function:
6. Emotion
identification
The capacity to identify the facial expressions of basic emotion
displayed by others.
Emotion
identification
task
Percentage correct, response time for each
expression (fear, anger, sadness, happiness,
disgust, neutral)
See Williams et al. (2010) for more detail about the tasks [1].
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defined in Section 7.3.2.
The secondary endpoints will be improvements after
ATMX treatment in quality of life (PedsQL - self and
parent); emotional states and self-regulation (DASS-
BRISC); and state and trait anxiety (CPRS-R subscales:
Anxious-shy, STAI and STAIC). Previous ADHD treat-
ment with stimulant medication and comorbid anxiety
will be included as covariates.
6. Adverse events and safety monitoring
Parents are advised to contact the CTC in the case of
any adverse events - defined as any physical, behavioral/
psychological, or physiological problems potentially
related to the study treatment or testing sessions. In the
case of mild adverse reactions, the parent will be asked
to continue on the study treatment and monitor the
condition, informing the CTC if the problem persists or
worsens. The study clinician will also be available for
the CTC to obtain a sound medical opinion if required.
If the adverse reaction is deemed an emergency, the par-
ents will be advised to take the participant to the Emer-
gency department of their nearest hospital. In these
situations, the participant’s group allocation will be
revealed in order to inform the hospital of what the par-
ticipant was administered. All adverse events will be
recorded.
The investigators will be responsible for monitoring
the safety of study participants and to take appropriate
action concerning any event that seems unusual. They
will ensure that appropriate medical care is maintained
throughout the study and after the study to follow
adverse events.
7. Statistical analysis
7.1. Sample size
The data used for the power calculation of the inhibi-
tion function primary outcome measures are from a
sample of 175 ADHD individuals assessed off and then
on stimulant medication (methylphenidate or dexam-
phetamine; data not published). The power calculation
of the emotional function primary outcome measures
are based on a sample of 30 ADHD participants from
the same sample.
Power was set at 0.9, alpha level at 0.05, and the mean
difference (change in off-versus on-medication) and
standard deviations for the mean of the n = 175 group
was used. The means for the n = 30 group were set at
‘0’, since there was no change expected in these out-
come measures for the placebo group. After applying
the pilot data means from each primary outcome mea-
sure the highest sample size estimate we obtained was n
= 152 for each group under two-tailed conditions.
Therefore, a minimum total of 152 participants are
required in this cross-over study to achieve the desired
level of probability in detecting a statistically significant
difference across the two primary outcome measures.
7.2. Data upload and reports
A computerized protocol will quantify cognitive data in
a standardized manner. Responses obtained from the
questionnaires will be paper-based, and entered into
computer-based scoring spreadsheets which have been
set up to automatically score each questionnaire. Raw
and composite IntegNeuro™ data for all sites will be
extracted and stored by the Brain Resource Company
Ltd., which will be periodically forwarded to the Sydney
site (once per month).
IntegNeuro™reports (from Brain Resource Company
Ltd.) will be generated and sent to the referring study
clinicians after Session 1 and Session 3 testing. These
reports will present performance at Session 1 compared
to normative data, and after Session 3 (comparing per-
formance after Session 2 and Session 3, including com-
parisons to normative data).
7.3. Data analysis
The ACTION study will adopt an all available data ana-
lytical approach, meaning that all data obtained will be
included in analyses, regardless of adherence to the
study. Accordingly, there will be no imputation of miss-
ing data. For all analyses, a p value of <0.05 will be con-
sidered statistically significant.
7.3.1. Baseline analyses Continuous data at baseline
will be checked for normality of distribution and log-
transformed if required. Logistic regression models will
be used to determine whether or not the cognitive and
emotion measures (using the composite scores) predict
the presence of comorbid anxiety (as determined using
the ADISC questionnaire).
7.3.2. Predictors and moderators of response to treat-
ment Simple linear regression models will be used to
observe any relationships between cognition/emotion
composite scores at baseline and questionnaire scores
after ATMX treatment to see if the objectively-mea-
sured cognition/emotion measures are related to the
subjectively-measured ADHD symptom measures
( A D H D - R SI V ,C P R S - R ) .T oe x a m i n et h epredictive
relationship of cognition/emotion measures on ADHD
symptom measures, changes after ATMX treatment in
ADHD symptom measures will be categorized depend-
ing on whether or not they responded to the treatment.
Analyses will be performed using two different defini-
tions of treatment response: 1) ≥25% improvement and
2) ≥40% improvement; while non-response will be
defined as 3) <25% improvement and 4) <40% improve-
ment [11,17,19,52]. More specifically regarding the pri-
mary outcome, six predictors (the composite scores
from baseline for the six cognition and emotional func-
tion markers, Table 1) will be used in logistic regression
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measures predict response to ATMX. Response in terms
of the primary outcome will be defined initially as a
≥25% improvement (versus <25% improvement) in
ADHD-RS IV and CPRS-R t scores (see Section 5). A
secondary, more stringent definition of response will
subsequently be implemented, using a response cut-
point of ≥40%. With a planned sample size of >60, these
analyses will be sufficiently powered. Further exploratory
analyses may be performed at a later date.
Absolute change scores (continuous ADHD symptom
data) will be used to see if the cognition/emotion mea-
sures moderate response to ATMX in ADHD symptom
measures. These investigations will initially be performed
on the total ADHD cohort, before examining any differ-
ences between those with and without comorbid anxiety.
7.3.3. Post treatment Repeated measures analysis of
variance (ANOVA) will be performed on continuous
variables (see Section 5), comparing the results obtained
between baseline and ATMX, baseline and Placebo, and
between ATMX and Placebo. Cohen’s d effect size will
be calculated using the mean differences between base-
line and ATMX, and baseline and Placebo. Analyses will
be performed in the total cohort, and then comparing
those with and without comorbid anxiety. Presence/
absence of previous stimulant treatment for ADHD, and
an interaction term between presence/absence of
comorbid anxiety and previous stimulant treatment will
be used as covariates.
Results and Discussion
The ACTION study will be a multi-site, double-blinded,
randomized cross-over study examining the effects of
ATMX on cognitive and emotional functions in children
and adolescents with ADHD, whilst also identifying
objective predictors of ATMX response in this group,
including those with and without comorbid anxiety. The
cross-over design of the study enables participants to
act as their own controls when testing whether cognitive
and emotional function at baseline is able to predict
changes in symptom ratings after medication treatment.
Enrolment and testing commenced in March 2008.
Potential limitations in the study design pertain to the
one-week washout period between treatment phases,
and the absence of an “anxiety only” arm for examining
comorbid anxiety outcomes. Although our selection of a
washout period of one-week’s duration was based on
previous research [53-55], it is not known if any carry
over effects were present. However, it is highly unlikely
that the results obtained after six weeks of placebo treat-
ment could be attributed to ATMX in those participants
receiving active treatment (ATMX) in Phase A. Future
studies may consider observing changes at first response
and full response, and to vary the length of their
washout periods between treatments. Additionally, an
anxiety only arm should also be incorporated if investi-
gating changes in comorbid anxiety outcomes.
Conclusions
The detailed methodology for the ACTION study has
been presented. The novelty of this trial lies in its utili-
zation of objective measures for cognition and emotion;
and in its combination of objective and subjective, com-
monly-used assessment tools to determine the efficacy
of ATMX in ADHD with and without comorbid anxiety.
This research will further our knowledge on the effec-
tive use of ATMX in improving symptoms in child and
adolescent ADHD; providing additional evidence to aid
in personalized treatment approaches.
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